Cargando…
Hyperprogression under Immunotherapy
Immunotherapy is now widely prescribed in oncology, leading to the observation of new types of responses, including rapid disease progression sometimes reported as hyperprogression. However, only a few studies have assessed the question of hyperprogression and there is no consensual definition of th...
Autores principales: | Frelaut, Maxime, Le Tourneau, Christophe, Borcoman, Edith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600249/ https://www.ncbi.nlm.nih.gov/pubmed/31151303 http://dx.doi.org/10.3390/ijms20112674 |
Ejemplares similares
-
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness
por: Borcoman, Edith, et al.
Publicado: (2017) -
Hyperprogression: A novel response pattern under immunotherapy
por: Han, Xue‐jiao, et al.
Publicado: (2020) -
Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borcoman, Edith, et al.
Publicado: (2021) -
Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
por: Borcoman, Edith, et al.
Publicado: (2020) -
Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)